Fluvoxamine is Poorly Tolerated by Alcoholics
Fluvoxamine maleate is a monocyclic antidepressant that potently and selectively inhibits presynaptic serotonin reuptake (Claasen et al. 1977). In addition to their antidepressant effects, selective serotonin-uptake inhibitors (SUIs), have been shown to reduce ethanol consumption in both rodents and non-depressed, heavy drinking humans (Gorelick 1986, Naranjo et al. 1984, 1986, 1987, 1989, 1990). To test the utility of fluvoxamine as an adjunct to relapse prevention treatment, we conducted an open trial (OT) in 16 subjects (13 males) and then initiated a placebo-controlled, double-blind trial (CT) in 19 subjects (18 males). All subjects met DSM III-R criteria for alcohol dependence (APA 1987). Subjects were excluded if they met criteria for current drug (other than nicotine) dependence or if they had a medical or psychiatric disorder that contraindicated treatment with fluvoxamine.
KeywordsPlacebo Depression Nicotine Serotonin Fluoxetine
Unable to display preview. Download preview PDF.